To minimize potential side effects,
doctors most often use transplanted stem cells that match the patient’s
own stem cells as closely as possible. People have different sets of proteins, called human leukocyte-associated (HLA) antigens, on the surface of their cells. The set of proteins, called the HLA type, is identified by a special blood test.
In
most cases, the success of allogeneic transplantation depends in part
on how well the HLA antigens of the donor’s stem cells match those of
the recipient’s
stem cells. The higher the number of matching HLA antigens, the greater
the chance that the patient’s body will accept the donor’s stem cells.
In general, patients are less likely to develop a complication known as
graft-versus-host disease (GVHD) if the stem cells of the donor and
patient are closely matched.
Close
relatives, especially brothers and sisters, are more likely than
unrelated people to be HLA-matched. However, only 25 to 35 percent of
patients have an HLA-matched sibling. The chances of obtaining
HLA-matched stem cells from an unrelated donor are slightly better,
approximately 50 percent. Among unrelated donors, HLA-matching is
greatly improved when the donor and recipient have the same ethnic and
racial background. Although the number of donors is increasing overall,
individuals from certain ethnic and racial groups still have a lower
chance of finding a matching donor. Large volunteer donor registries can
assist in finding an appropriate unrelated donor.
Because identical twins have the same genes,
they have the same set of HLA antigens. As a result, the patient’s body
will accept a transplant from an identical twin. However, identical
twins represent a small number of all births, so syngeneic
transplantation is rare.
This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment